Evidence map›Paper›PMID 29777624›Full record

ArticleThe FEBS journal2018

Characterisation of a putative glutamate 5-kinase from Leishmania donovani.

Natasha Sienkiewicz, Han B Ong, Alan H Fairlamb

Open access · hybridAbstract read
In one paragraph

Article in The FEBS journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Natasha SienkiewiczDivision of Biological Chemistry & Drug Discovery, School of Life Sciences, University of Dundee, UK.
Han B OngDivision of Biological Chemistry & Drug Discovery, School of Life Sciences, University of Dundee, UK.
Alan H FairlambDivision of Biological Chemistry & Drug Discovery, School of Life Sciences, University of Dundee, UK.ORCID 0000-0001-5134-0329
University of Dundee · GB

Funding

Wellcome Trust 079838Wellcome Trust 203134/Z/16/Z
6 · The paper itself

Abstract

Previous metabolic studies have demonstrated that leishmania parasites are able to synthesise proline from glutamic acid and threonine from aspartic acid. The first committed step in both biosynthetic pathways involves an amino acid kinase, either a glutamate 5-kinase (G5K; EC2.7.2.11) or an aspartokinase (EC2.7.2.4). Bioinformatic analysis of multiple leishmania genomes identifies a single amino acid-kinase gene (LdBPK 262740.1) variously annotated as either a putative glutamate or aspartate kinase. To establish the catalytic function of this Leishmania donovani gene product, we have determined the physical and kinetic properties of the recombinant enzyme purified from Escherichia coli. The findings indicate that the enzyme is a bona fide G5K with no activity as an aspartokinase. Tetrameric G5K displays kinetic behaviour similar to its bacterial orthologues and is allosterically regulated by proline, the end product of the pathway. The structure-activity relationships of proline analogues as inhibitors are broadly similar to the bacterial enzyme. However, unlike G5K from E. coli, leishmania G5K lacks a C-terminal PUA (pseudouridine synthase and archaeosine transglycosylase) domain and does not undergo higher oligomerisation in the presence of proline. Gene replacement studies are suggestive, but not conclusive that G5K is essential. ENZYMES: Glutamate 5-kinase (EC2.7.2.11); aspartokinase (EC2.7.2.4).

Indexed as

Amino Acid SequenceAspartic AcidBiocatalysisCloning, MolecularEscherichia coliGene ExpressionGenetic Complementation TestGenetic VectorsGlutamic AcidHumansKineticsLeishmania donovaniPhosphotransferases (Carboxyl Group Acceptor)PhylogenyProlineProtein BindingAspartic Acidglutamate 5-kinaseGlutamic AcidPhosphotransferases (Carboxyl Group Acceptor)ProlineProtozoan ProteinsRecombinant Proteinsbiochemical pathwaydrug targetinhibitorsLeishmaniaproline biosynthesis

Identifiers

PMID29777624
PMCPMC6099280
OpenAlexW2804595444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.